Recent News

• 03.24.2026 - Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
• 03.10.2026 - Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
• 03.03.2026 - Opus Genetics to Present at Upcoming Investor Conferences in March 2026
• 02.27.2026 - Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
• 02.25.2026 - Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
• 02.13.2026 - Opus Genetics Announces $25 Million Private Placement

Recent Filings

• 03.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.16.2026 - 144 Report of proposed sale of securities
• 03.13.2026 - S-3 Registration statement under Securities Act of 1933
• 03.12.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.12.2026 - PRE 14A Other preliminary proxy statements
• 03.10.2026 - EX-99.1 EX-99.1
• 03.10.2026 - 8-K Current report